What has driven Datascope at every turn has been innovation.
Breaking new ground in medical technology has grown the Company steadily over the last 40 years.
In 2006, Datascope has 1300 employees and worldwide sales of over $350 million. Today, Datascope manufactures products found throughout
the modern hospital – in interventional cardiology and radiology, in
anesthesiology, in cardiovascular surgery, in emergency medicine and
in critical care.
Hospitals that count on Datascope products can be found in over 80 countries across the world. We have direct sales and service organizations in the U.S., U.K., France, Germany, Italy, Belgium and the Netherlands. We serve Central and Latin America, Europe, Middle East and Africa, Asia Pacific, Australia and Canada through our large distributor network. The Company went public in 1972, and is traded on NASDAQ under the ticker symbol DSCP. Today, the Company has no debt, working capital of $126 million and Dun and Bradstreet’s highest credit rating of 5A1.
The most telling facts about Datascope are not found in the balance sheet. They have to do with the medical advances that we have pioneered over the last 40 years. To us, innovation has never meant momentary advantage over competition. It has always meant dramatically advancing the state of the art. A glance at the Datascope Timeline, we hope, will give you a small sense of it.
